In a research report issued Friday, Needham analyst Alan Carr reiterated a Buy rating on shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) with a price …
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that the pivotal in Tandem1 Phase 3 clinical trial of sotagliflozin met its primary endpoint, showing a statistically …
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that the U.
Amazon.com, Inc.
Analysts are weighing in on the development-stage company Celldex Therapeutics, Inc. (NASDAQ:CLDX) and pharmaceutical company Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) reported financial results for the third quarter ended September 30, 2015 and provided an overview of key milestones for …
Lexicon Pharmaceuticals, Inc.’s (NASDAQ:LXRX) telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements …
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), telotristat etiprate was shown to have clinical benefit in treating carcinoid syndrome in cancer patients not adequately controlled by …
In a research report released Monday, Wedbush’s healthcare analyst Liana Moussatos reiterated an Outperform rating on shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) with a $19 …
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that data from its Phase 2 clinical study of sotagliflozin in type 1 diabetes will be presented in oral …